Beijing Tong Ren Tang Chinese Medicine (HKG:3613) recorded a 21% decline in attributable profit for 2025 to HK$397.2 million from HK$500.3 million a year prior, according to a Friday Hong Kong bourse filing.

Shares of the medicine manufacturer were down nearly 5% in Monday afternoon trading.

Earnings per share stood at HK$0.47, down from HK$0.60 in the corresponding period of the last fiscal year.

Revenue slipped 6.1% year over year to HK$1.51 billion from HK$1.61 billion driven by an 11.9% decline in revenue in the Hong Kong market and an 18.3% drop in revenue in the Chinese mainland market.

The company recommended a final dividend of HK$0.37 per share and a special dividend of HK$0.03 per share for the year, payable on or before June 26 to shareholders of record on June 18, subject to shareholder approval.